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Neuropsychiatric symptoms in 921 elderly
subjects with dementia: a comparison between
vascular and neurodegenerative types
Caputo M, Monastero R, Mariani E, Santucci A, Mangialasche F,
Camarda R, Senin U, Mecocci P. Neuropsychiatric symptoms in 921
elderly subjects with dementia: a comparison between vascular and
neurodegenerative types.
Objective: i) to describe the neuropsychiatric proﬁle of elderly
subjects with dementia by comparing vascular (VaD) and degenerative
dementias, i.e. dementia with Lewy bodies (DLB) and Alzheimers
disease (AD); ii) to assess whether the severity and type of dementia
are associated with clinically relevant neuropsychiatric symptoms
(CR-NPS).
Method: One hundred and thirty-one out-patients with VaD, 100 with
DLB and 690 with AD were studied. NPS were evaluated by the
neuropsychiatric inventory (NPI).
Results: Vascular dementia had lower total and domain-speciﬁc NPI
scores and a lower frequency of CR-NPS than AD and DLB, for which
frequency of CR-NPS increased signiﬁcantly with disease severity,
particularly in AD. Logistic regression analysis showed that a higher
CDR score and a diagnosis of degenerative dementia were
independently associated with CR-NPS.
Conclusion: Vascular dementia is associated less with CR-NPS than
AD and DLB. Frequency of CR-NPS increases with disease severity in
AD and, to a lesser extent, in DLB.
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Significant outcomes
• Neuropsychiatric symptoms were evaluated in a large sample of elderly subjects referred to a
specialty clinical service. The most prevalent types of dementia (i.e. vascular dementia, dementia with
Lewy bodies and Alzheimers disease) were compared.
• Neuropsychiatric symptoms were evaluated with NPI, a validated, standardized and widely used
instrument that was developed speciﬁcally for neuropsychiatric symptoms of dementia.
• Diagnosis of a degenerative type of dementia and its severity were independently associated with
clinically relevant neuropsychiatric symptoms.
Limitations
• Neuropsychiatric symptoms were evaluated in a sample of elderly out-patients with low educational
status who had mainly moderate stage dementia. Potential limitations are selection bias, reporter bias
and whether results can be generalized.
• Residual confounders (e.g. use of psychotropic drugs, medical comorbidity and apolipoprotein E4
genotype) cannot be excluded, although most patients were not under treatment with antipsychotic
drugs at the time of enrolment.
• Difference in prevalence of neuropsychiatric symptoms between data from this study and previous
reports may depend upon sensitivity of instruments (NPI vs. other scales) and setting (clinical vs.
population study).
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Introduction
Dementia is characterized by changes in cognitive,
behavioural, psychological and functional capaci-
ties. Although cognitive deﬁcits and decline in daily
functioning are, according to the Diagnostic and
Statistical Manual of Mental Disorders (DSM IV-
TR) (1), the main clinical features in the diagnosis
of dementia, much evidence over the past decade
has established neuropsychiatric symptoms (NPS)
as fundamental clinical features (2). NPS, which
include behavioural and psychological symptoms,
are associated with poor prognosis (3), excess
disability (4), impaired quality of life for subjects
and carers (5), high levels of caregiver distress
(6, 7), early institutionalization (3) and increased
direct cost of care (8).
The frequency of NPS in dementia ranges from
25% to 80% (9, 10), probably due to methodo-
logical diﬀerences and heterogeneous settings.
However, previous studies have investigated
mainly subjects with Alzheimers disease (AD) (9,
11, 12) and few have been conducted in subjects
with vascular dementia (VaD) (10, 13–15) or
dementia with Lewy bodies (DLB) (16, 17).
According to previous ﬁndings, AD seems to be
characterized by diﬀerent behavioural syndromes
(12, 18), which include prominent mood symptoms
(i.e. depression, anxiety and apathy), psychotic
disturbances (i.e. delusions and hallucinations),
agitation-related symptoms (i.e. aggression and
irritability) and ⁄or symptoms of behavioural dys-
control (i.e. euphoria, disinhibition, aberrant
motor behaviour, sleep and appetite disturbances).
Depression, anxiety and apathy, as well as irrita-
bility and psychotic disturbances, have been fre-
quently described in subjects with VaD (19). Visual
hallucinations, reported as diagnostic clinical fea-
tures of DLB, are commonly observed during the
course of the disease and may be the initial reason
for referral; delusions, apathy, anxiety and depres-
sion are other NPS often associated with DLB
(20, 21).
A previous report of NPS in dementias showed
that VaD and DLB have a higher frequency of
NPS than AD, although results are discordant
and most refer to small case series (13, 16).
Hence, the frequency of individual NPS in sub-
jects with diﬀerent types of dementia is still
controversial.
Another important issue is the occurrence of
NPS in the diﬀerent stages of dementia (9, 11, 22,
23). Mood symptoms generally develop early in the
course of the disease, while psychotic symptoms
and agitation characterize the middle to late stages
of dementia. Some NPS, such as depression or
delusions and hallucinations, have been investi-
gated in depth with speciﬁc instruments in subjects
with dementia; others, like apathy or wandering,
less so. In the last decade, numerous studies
focused on developing standardized comprehensive
scales for assessing NPS in dementia. Among them,
the Neuropsychiatric Inventory (NPI) (24),
appears to be a useful, reliable tool for assessing
a wide spectrum of NPS and the Clinical Antipsy-
chotic Trials of Intervention Eﬀectiveness (CATIE)
research program recently deﬁned as clinically
relevant a neuropsychiatric symptom that is
severe enough to require treatment (NPI score
‡4) (25).
Aims of the study
We characterized the frequency and severity of
neuropsychiatric symptoms using the NPI scale in
a large sample of subjects with dementia referred to
a clinical center and compared vascular dementia
with the two most common forms of neurodegen-
erative dementias (i.e. dementia with Lewy bodies
and Alzheimers disease). Furthermore, we evalu-
ated the impact of severity and type of dementia on
expression of clinically relevant neuropsychiatric
symptoms.
Material and methods
Subjects
From January 2001 to December 2005, 1235
subjects with dementia, all living at home, were
consecutively seen at the Memory Clinic, Centre
for the Study of Brain Aging and Senile Demen-
tias, University of Perugia, Italy. The diagnostic
work-up included a complete medical history,
clinical and neurological examinations, laboratory
testing, and neuroimaging with computed tomog-
raphy or magnetic resonance imaging of the brain.
All subjects or next-of-kin provided written
informed consent as requested by the local ethical
committee. All subjects underwent a complete
neuropsychological evaluation. This included the
Mini-Mental State Examination (MMSE) as a
measure of global cognition followed by a speciﬁc
battery of tests – the Babcock Story Recall, the Rey
Auditory Verbal Learning test immediate and
delayed recall, the Corsi Block Tapping test, the
Token test, the Category Naming test, the Con-
trolled Oral Word Association test, the Visual
Search test and the Ravens Coloured Progressive
Matrices. For each test, details on administration
procedures and Italian normative data for score
adjustment based on age, gender and education as
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well as normality cut-oﬀ scores (‡95% of the lower
tolerance limit of the normal population distribu-
tion) are available (26–28).
The severity of dementia was rated using the
Clinical Dementia Rating scale (CDR) (29) whose
score ranges from 0 (no cognitive decline) to 3
(severe dementia). Functional status was measured
by Katzs index of activity of daily living (ADL)
(30) whose score ranges from 0 (complete indepen-
dence) to 6 (total dependence).
The diagnosis of dementia was made according
to the DSM-IV-TR (1). AD was then diagnosed
according to NINCDS-ADRDA criteria (31), VaD
using the NINDS-AIREN criteria (32), DLB
according to DLB consortium criteria (33), and
frontal–temporal dementia (FTD) according to the
Lund and Manchester criteria (34). Physicians who
performed the diagnosis were blinded to the results
of neuropsychological battery and the NPI.
Dementia was ﬁrst diagnosed after a discussion
among geriatricians (M.C., E.M.) who examined
the patients, after collecting the history, perform-
ing the clinical examination, evaluating the labo-
ratory ﬁndings and the results of neuroimaging.
Results of MMSE, CDR and ADL were also used.
A further evaluation was then made by neurolo-
gists (R.M., R.C.) who were external to the
recruitment process. If ﬁrst and second diagnoses
did not concur, data were re-examined indepen-
dently by a senior geriatrician (P.M.) who made
the ﬁnal diagnosis. Kappa statistics evaluated the
reliability of diagnosis between geriatricians and
neurologists (35). As previously reported (36),
combining NINCDS-ADRDA possible and proba-
bleAD categories (n = 68), there was a good inter-
observer agreement (kappa = 0.71).
One hundred and ﬁfty-six subjects with dementia
due to other general medical conditions (DSM-IV-
TR code 294.1), such as head trauma, severe
metabolic or endocrine diseases, brain tumour,
normal pressure hydrocephalus and other neuro-
logical disorders were excluded as well as subjects
with a history of alcohol or substance abuse or
dependence, with uncertain dementia, with delir-
ium and with psychiatric disorders preceding the
onset of dementia. In this latter group, we included
subjects with a DSM-IV-TR diagnosis of mood
disorders, psychotic disorders and personality disor-
ders requiring chronic treatment with psychotropic
drugs started before age 60 (1).
One hundred and thirty-two subjects, who were
diagnosed as having possible VaD, DLB, AD and
FTD were also excluded from the study. Of the
remaining 947 subjects, 131 subjects fulﬁlled crite-
ria for probable VaD, 100 subjects for probable
DLB, 690 for probable AD and 26 subjects for
probable FTD. The latter group, being so small,
was then excluded from data analyses, which refers
to 921 subjects (Fig. 1).
Assessment of neuropsychiatric symptoms
NPS were evaluated by NPI (24), a fully structured
caregiver interview with 12 sub-scales measuring
the following symptoms: delusions, hallucinations,
agitation, dysphoria, anxiety, apathy, irritability,
euphoria, disinhibition, aberrant motor behaviour,
sleeping and eating abnormalities. Each sub-scale
has an entry question inquiring whether the
disturbance had been present in the last month. If
the answer is aﬃrmative, the caregiver is asked to
rate speciﬁc neurobehavioural symptoms within
each sub-scale on a four-point frequency and on a
three-point severity scale. Frequency and severity
scores are multiplied for each sub-scale (composite
score) and added together for the total NPI score.
The composite score of each sub-scale ranges
between 0 and 12, and the total composite score
between 0 and 144 according to the severity and
frequency of NPS. An NPI score of 4 or more for
any symptom indicates clinical relevance and is
considered entry criteria for treatment trials of
dementia-associated NPS (25). The scale has a high
level of internal consistency reliability, inter-rater
reliability and the test–retest reliability, and has
been validated in Italian subjects (37). As previ-
ously reported (37), inter-observer agreement on
the presence ⁄absence of clinically relevant NPS in
subjects with probable AD (n = 46) was almost
perfect between the two raters who administered
the NPI (percentage of agreement for each NPI
sub-scale ranged from 87.6% to 95.5%).
Statistical analysis
Demographic and clinical variables among groups
were evaluated with one-way analysis of variance
(anova) with post-hoc Scheﬀes test for multiple
comparisons and chi-square analysis followed by
Fishers exact test, as needed. Frequencies of
clinically relevant NPI domains (frequency ·
severity score ‡4) were also evaluated with
chi-square analysis followed by Fisher’s exact test.
All tests were two tailed.
Logistic regression analysis assessed the associ-
ation between each clinically relevant NPI symp-
tom (dependent variable) and severity and type of
dementia (independent variables).
Severity of dementia (CDR score) and type of
dementia (VaD, DLB, AD) were analysed in two
logistic regression models. The basic model was
adjusted for age, gender, education and ADL score
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(expressed as continuous variables); then it was
adjusted for all these parameters plus either type of
dementia (model 1) or CDR score (model 2).
Results are presented as odds ratios (OR) with
95% conﬁdence intervals (95% CI). For all anal-
yses, signiﬁcance level was set at P < 0.05. Statis-
tical analysis was performed with spss version 12.0
(SPSS, Inc., Chicago, IL, USA).
Results
anova revealed a signiﬁcant age-eﬀect between
groups. However, Scheﬀe’s post-hoc analyses did
not reveal statistical diﬀerences between groups at
pair-comparison. Education, MMSE and CDR
scores did not diﬀer among groups. Subjects with
VaD and DLB showed a signiﬁcantly higher ADL
score than those with AD. The percentage of
women was signiﬁcantly lower in VaD and DLB
than in AD (Table 1).
Patients with VaD had a lower mean composite
score in most NPI domains than DLB and AD,
scoring signiﬁcantly less in delusions, hallucina-
tions, agitation ⁄aggression, irritability and aberrant
motor behaviour than patients withDLB and less in
anxiety and aberrant motor behaviour than patients
with AD. Subjects with DLB had signiﬁcantly
higher scores in agitation ⁄aggression and disinhibi-
tion than those with AD and a higher total
composite NPI score than subjects with VaD and
AD (Table 2).
Clinically relevant NPS (NPI ‡4) were common
in all groups. One or more were present in 84.7%
subjects with VaD, 96.0% with DLB and 90.6%
with AD. Subjects with VaD showed a lower
frequency of clinically relevant NPS, with signiﬁ-
cant diﬀerences for hallucinations (vs. DLB),
agitation ⁄aggression (vs. DLB and vs. AD), anx-
iety (vs. DLB and vs. AD), irritability (vs. DLB)
and aberrant motor behaviour (vs. AD). Disinhi-
bition was signiﬁcantly more frequent in DLB than
in AD (Table 3).
In VaD, only frequency of clinically relevant
apathy and aberrant motor behaviour increased
signiﬁcantly with disease progression. In DLB,
the frequency of clinically relevant delusions,
hallucinations, disinhibition and sleep distur-
bances was signiﬁcantly higher in subjects with
Consecutive out-patients 
with dementia  
n = 1235 
  156 subjects with: 
 - post-traumatic dementia  
 - dementia due to metabolic causes 10  
8 
 - dementia due to endocrine disorders   7 
 - dementia due to alcohol or substance abuse  28  
 - dementia due to brain tumor  12  
 - dementia associated with normal pressure  
  hydrocephalus  8 
 - dementia due to other  neurological diseases  19  
 - uncertain dementia  23  
 - delirium   6 
 - dementia associated with treated psychiatric 35  
 illness before age 60  
Out-patients with possible 
and probable VaD,  DLB,  
AD and FTD  
n = 1079  
Out-patients with probable 
VaD, DLB, AD and FTD  
n = 947  
probable FTD = 26 
Out-patients with probable, 
VaD, DLB and AD 
n = 921    
VaD = 131  
DLB = 100  
AD = 690  
132 subjects with possible dementia   
- possible VaD   38  
- possible DLB   19  
- possible AD   67  
- possible FTD     8 
Fig. 1. Flow-chart diagram of forma-
tion of the study sample.
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moderate–severe dementia than in those with mild
dementia. In AD, except for anxiety and depres-
sion, the frequency of clinically relevant NPS,
increased with severity of dementia. Anxiety
tended to decrease as dementia became more
severe; depression was signiﬁcantly more frequent
in moderate than in mild or severe AD (Table 4).
Logistic regression analysis with mild demen-
tia (CDR 1) as reference group showed that
moderate dementia (CDR 2) was signiﬁcantly
Table 2. Mean composite scores (frequency ·
severity) of individual NPI symptoms in subjects with
VaD, DLB and AD
NPI item VaD (n = 131) DLB (n = 100) AD (n = 690) P-value Post-hoc*
Delusions 1.2 (2.5) 2.2 (3.3) 1.7 (2.9) 0.04 VaD < DLB
Hallucinations 0.6 (1.4) 1.4 (2.7) 1.0 (2.3) 0.02 VaD < DLB
Agitation ⁄ aggression 2.3 (2.8) 3.8 (4.0) 2.9 (3.3) 0.002 VaD, AD < DLB
Depression 3.1 (3.4) 3.0 (3.2) 3.2 (3.5) 0.89
Anxiety 2.1 (2.8) 3.1 (3.3) 3.0 (3.2) 0.01 VaD < AD
Euphoria 0.4 (1.6) 0.4 (1.2) 0.3 (1.2) 0.80
Apathy 3.8 (3.4) 4.8 (4.0) 4.1 (3.9) 0.13
Disinhibition 0.9 (2.2) 1.4 (2.6) 0.8 (2.0) 0.02 AD < DLB
Irritability 2.2 (2.9) 3.4 (3.4) 2.8 (3.1) 0.005 VaD < DLB
Aberrant motor behaviour 1.3 (3.0) 2.4 (3.6) 2.2 (3.4) 0.01 VaD < DLB, AD
Sleep 2.0 (3.0) 2.6 (3.6) 2.0 (3.2) 0.22
Eating 1.2 (2.6) 1.8 (3.3) 1.5 (3.0) 0.28
Total NPI 20.0 (16.0) 30.4 (21.1) 24.3 (18.6) <0.001 VaD, AD < DLB
VaD, vascular dementia; DLB, dementia with Lewy bodies; AD, Alzheimer disease; NPI, neuropsychiatric inventory.
Data are expressed as mean (SD) unless otherwise specified.
*ANOVA with post-hoc Scheffe's test.
Table 1. Demographic and clinical data of subjects
with VaD, DLB and AD Demographic and clinical
variables
VaD
(n = 131)
DLB
(n = 100)
AD
(n = 690) P-Value Post-hoc*
Age (years) 77.9 (6.9) 77.8 (7.5) 76.4 (7.8) 0.03
Education (years) 5.6 (4.2) 5.1 (3.4) 5.1 (3.7) 0.31
ADL score 2.9 (1.9) 2.9 (1.9) 2.1 (1.9) <0.001 AD < VaD, DLB
MMSE score 15.0 (6.2) 14.0 (7.4) 14.7 (6.5) 0.51
CDR score 2.0 (0.6) 2. 1 (0.7) 2.1 (0.7) 0.36
Women, n (%) 72 (55.0) 51 (51.0) 487 (70.6) <0.001 VaD, DLB < AD
Dementia severity (CDR score), n (%): 0.22
CDR 1 (mild) 27 (20.6) 21 (21.0) 138 (20)
CDR 2 (moderate) 79 (60.3) 47 (47.0) 376 (54.5)
CDR 3 (severe) 25 (19.1) 32 (32.0) 176 (25.5)
VaD, vascular dementia; DLB, dementia with Lewy bodies; AD, Alzheimer disease; ADL, activity of daily living; MMSE,
mini-mental state examination; CDR, clinical dementia rating.
Data are expressed as mean (SD) unless otherwise specified.
*ANOVA with post-hoc Scheffe's test (ADL) or chi-square with Fishers exact test (gender).
Table 3. Frequency of clinically relevant NPI symp-
toms (frequency · severity ‡4) in subjects with
VaD, DLB and AD NPI item VaD (n = 131) DLB (n = 100) AD (n = 690) P-value
Two-by-two
comparison*
Delusions 22 (16.8) 27 (27.0) 156 (22.6) 0.17
Hallucinations 10 (7.6) 18 (18.0) 87 (12.6) 0.06 VaD < DLB
Agitation ⁄ aggression 38 (29.0) 48 (48.0) 286 (41.4) 0.008 VaD < DLB, AD
Depression 57 (43.5) 38 (38.0) 278 (40.3) 0.68
Anxiety 40 (30.5) 46 (46.0) 289 (41.9) 0.03 VaD < DLB, AD
Euphoria 5 (3.8) 5 (5.0) 29 (4.2) 0.90
Apathy 72 (55.0) 60 (60.0) 354 (51.3) 0.23
Disinhibition 16 (12.2) 20 (20.0) 66 (9.6) 0.007 AD < DLB
Irritability 44 (33.6) 51 (51.0) 273 (39.6) 0.02 VaD < DLB
Aberrant motor behaviour 22 (16.8) 30 (30.0) 218 (31.6) 0.003 VaD < AD
Sleep 35 (26.7) 32 (32.0) 174 (25.2) 0.35
Eating 20 (15.3) 24 (24.0) 132 (19.1) 0.25
VaD, vascular dementia; DLB, dementia with Lewy bodies; AD, Alzheimer disease; NPI, neuropsychiatric inventory.
Data are expressed as n (%) unless otherwise specified.
*Chi-square with Fishers exact test.
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associated with clinically relevant hallucina-
tions, depression and apathy. Severe dementia
(CDR 3) was signiﬁcantly associated with clini-
cally relevant delusions, hallucinations, apathy,
disinhibition and aberrant motor behaviour
(Table 5).
Logistic regression analysis with VaD as refer-
ence group showed DLB was signiﬁcantly associ-
ated with clinically relevant hallucinations,
agitation ⁄aggression, anxiety, irritability, and
aberrant motor behaviour and AD was signiﬁ-
cantly associated with clinically relevant delusions,
hallucinations, agitation ⁄aggression, anxiety, irri-
tability, aberrant motor behaviour and eating
disturbances (Table 5).
Discussion
The present study provides evidence that fre-
quency of clinically relevant NPS varies with the
type and severity of dementia, which were
independently associated with NPS expression.
In this study, subjects with DLB showed the
highest severity and frequency of clinically rele-
vant NPS. Unlike VaD, neurodegenerative
dementias, particularly AD, were associated
with more frequent NPS as cognitive impairment
worsened, thus conﬁrming previous results
(38, 39).
To our knowledge, this is the ﬁrst study to
evaluate NPS in a large sample of subjects with the
Table 4. Frequency of clinically relevant NPI symptoms (frequency · severity ‡4) according to dementia severity (CDR score) in subjects with VaD, DLB and AD
NPI item
CDR score in VaD, % CDR score in DLB, % CDR score in AD, %
1
(n = 27)
2
(n = 79)
3
(n = 25) P-value
Two-
by-two
comparison*
1
(n = 21)
2
(n = 47)
3
(n = 32) P-value
Two-
by-two
comparison*
1
(n = 138)
2
(n = 376)
3
(n = 176) P-value
Two-
by-two
comparison*
Delusions 14.8 16.5 20.0 0.88 14.3 21.3 43.8 0.03 1, 2 < 3 14.5 19.9 34.7 <0.001 1, 2 < 3
Hallucinations 0 8.9 12.0 0.22 0 19.1 28.1 0.03 1 < 2, 3 4.3 11.2 22.2 <0.001 1 < 2 < 3
Agitation ⁄
aggression
25.9 27.8 36.0 0.68 42.9 44.7 56.3 0.52 33.3 39.6 51.7 0.003 1, 2 < 3
Depression 33.3 49.4 36.0 0.25 38.1 44.7 2.1 0.33 31.2 45.7 35.8 0.004 1, 3 < 2
Anxiety 25.9 31.6 32.0 0.84 47.6 48.9 40.6 0.76 44.2 43.9 35.8 0.17
Euphoria 3.7 2.5 8.0 0.46 0 6.4 6.3 0.50 2.9 2.4 9.1 0.001 1, 2 < 3
Apathy 25.9 60.8 68.0 0.002 1 < 2, 3 61.9 63.8 53.1 0.62 38.4 52.4 59.1 0.001 1 < 3
Disinhibition 3.7 11.4 24.0 0.08 0 14.9 40.6 0.001 1, 2 < 3 5.8 8.2 15.3 0.007 1, 2 < 3
Irritability 37.0 31.6 36.0 0.84 47.6 53.2 50 0.91 38.4 35.6 48.9 0.01 2 < 3
Aberrant motor
behaviour
7.4 12.7 40.0 0.002 1, 2 < 3 19.0 31.9 34.4 0.46 17.4 26.9 52.8 <0.001 1 < 2 < 3
Sleep 14.8 26.6 40.0 0.12 4.8 34.0 49.9 0.005 1 < 2, 3 17.4 23.7 34.7 0.001 1, 2 < 3
Eating 11.1 13.9 24.0 0.38 23.8 14.9 37.5 0.07 10.1 19.4 25.6 0.003 1 < 2, 3
VaD, vascular dementia; DLB, dementia with Lewy bodies; AD, Alzheimer disease; NPI, neuropsychiatric inventory; CDR, clinical dementia rating.
*Chi-square with Fishers exact test.
Table 5. Association between clinically relevant NPI
symptoms (frequency · severity ‡4) and, respec-
tively, dementia severity (CDR score) or dementia
type
NPI item
CDR score (model 1) Diagnosis (model 2)
CDR 2 vs. CDR 1 CDR 3 vs. CDR 1 DLB vs. VaD AD vs. VaD
Delusions 1.2 (0.7–1.9) 1.9 (1.1–3.3) 1.7 (0.9–3.3) 1.7 (1.0–2.9)
Hallucinations 3.0 (1.3–7.3) 4.8 (1.9–12.1) 2.5 (1.1–5.9) 2.2 (1.1–4.5)
Agitation ⁄ aggression 1.0 (0.7–1.5) 1.4 (0.9–2.2) 2.2 (1.2–3.8) 2.1 (1.3–3.1)
Depression 1.5 (1.1–2.2) 0.9 (0.6–1.4) 0.8 (0.5–1.5) 0.9 (0.6–1.3)
Anxiety 0.9 (0.6–1.2) 0.6 (0.4–0.97) 2.0 (1.2–3.5) 1.6 (1.1–2.5)
Euphoria 0.8 (0.3–2.4) 1.9 (0.6–5.7) 1.1 (0.3–3.9) 1.1 (0.4–3.2)
Apathy 1.8 (1.2–2.6) 1.7 (1.1–2.7) 1.2 (0.7–2.1) 1.0 (0.7–1.5)
Disinhibition 1.8 (0.8–3.8) 3.4 (1.5–7.8) 1.6 (0.8–3.4) 0.9 (0.5–1.7)
Irritability 0.8 (0.5–1.1) 1.0 (0.7–1.6) 1.9 (1.1–3.3) 1.5 (1.0–2.2)
Aberrant motor behaviour 1.5 (0.95–2.4) 3.5 (2.1–5.9) 2.0 (1.0–3.8) 2.7 (1.6–4.5)
Sleep 1.2 (0.7–2.0) 1.4 (0.8–2.4) 1.2 (0.7–2.3) 1.4 (0.8–2.2)
Eating 1.3 (0.8–2.2) 1.5 (0.8–2.6) 1.8 (0.9–3.5) 1.7 (1.0–2.9)
Values are given as odds ratio (95% CI).
VaD, vascular dementia; DLB, dementia with Lewy bodies; AD, Alzheimer disease; NPI, neuropsychiatric inventory;
CDR, clinical dementia rating. Logistic regression analyses were adjusted for: age, gender, education, ADL score and
diagnosis (model 1); age, gender, education, ADL score and CDR score (model 2). Statistically significant results are
reported in bold type.
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three most common types of dementia using the
NPI, a comprehensive, standardized widely used
instrument (24).
Regardless of the type of dementia, these data
conﬁrm that NPS are very common in subjects
with dementia who have been referred to a memory
clinic. Concurring with previous reports on out-
patients (11, 38, 40), at least one NPS was found in
about 90% of cases. Apathy was extremely fre-
quent, being present in over 50% of subjects with
any type of dementia, thereby supporting previous
observations in VaD (19), DLB (21) and AD
(9–11).
In this study, VaD was associated with a lower
mean NPI score and fewer clinically relevant NPI
symptoms than DLB and AD. Unlike these results,
Lyketsos et al. (10) and Fuh et al. (41) found few
diﬀerences in the frequency and severity of NPS
(except for delusions and depression) in large
samples of subjects with VaD and AD. Even
though other studies (13, 14, 39–41) have reported
depression, anxiety and ⁄or apathy are more fre-
quent in subjects with VaD, this study found a
signiﬁcantly lower frequency of anxiety in VaD
than in DLB and AD but no diﬀerences in the
frequency of depression and apathy. Concerning
degenerative dementias, the severity and frequency
of most disturbances were particularly evident in
subjects with DLB, as previously reported (20, 21).
They were more evident than in patients with VaD
and, except for disinhibition and agitation, tended
to overlap with the pattern observed in AD. In
AD, the spectrum of clinically relevant NPS was
similar to previous reports (9–11): apathy was the
most frequent behavioural disturbance, with a high
prevalence of anxiety, agitation, depression; the
least common NPS was euphoria.
Severity of dementia was not always associated
with worsening NPS. In VaD, severity of disease
did not impact upon frequency of NPS, except for
apathy and aberrant motor behaviour, thereby
conﬁrming other reports (38, 39). However, dis-
crepancies in this study that reports that psychosis,
depression and anxiety were more common in
moderate and severe VaD (13, 14), may in part be
related to the relatively small sample size of the
VaD group and to the focus of this study on
clinically relevant NPS. On the contrary, in DLB
frequency of delusions, hallucinations, disinhibi-
tion and sleep problems increased with severity of
dementia. These data support a previous study
reporting that in DLB NPS are related, although
weakly, to severity of dementia (21). Interestingly,
in the mild stage of DLB visual hallucinations,
which are one of its core features (33), did not
reach the clinically relevant threshold. Unlike these
ﬁndings, Ballard et al. (17), reported depression,
delusion, hallucination and delusional misidentiﬁ-
cation were equally common in diﬀerent stages of
DLB. Again, discrepancies are probably due to our
decision to focus on clinically relevant distur-
bances. Indeed, when hallucinations – one of the
core symptoms of DLB – were considered only as
present (NPI score ‡1), they were found in 19% of
patients with DLB at mild, in 34% at moderate
and 41% at severe stage of dementia. In patients
with AD, severity of dementia was most often
associated with increased frequency of clinically
relevant NPS, as reported elsewhere (11, 22, 23,
42). Independently of disease severity and other
confounders (such as age, gender, disability, that
inﬂuence NPS) (22, 41, 43), suﬀering from DLB or
AD roughly doubles the risk of presenting clini-
cally relevant NPS compared with VaD.
Discrepancies in frequency rates and severity of
NPS across diﬀerent types and stages of dementia
may reﬂect diﬀerences in methodological and
statistical approaches. First, they may be due to
the diﬀerential sensitivity of instruments since
other studies used scales other than NPI or CDR
to evaluate NPS and dementia severity (14, 17, 39).
Second, this research focused on clinically relevant
symptoms, excluding subjects with very mild NPS,
so as to obtain robust observations on subjects
who often need not only pharmacological but also
non-pharmacological therapies. Third, diﬀerences
in demographics could account for discrepancies
since the study sample included elderly subjects,
with a low-educational status and who were mainly
at moderate stage of dementia. Lastly, the diﬀerent
study-setting (e.g. hospital based vs. population
based) may explain the diﬀerences observed in the
present study from those obtained at population
level (10).
Although psychological and social factors
contribute to the onset and persistence of NPS in
dementia (44), the diﬀerent proﬁles of clinically
relevant NPS which emerged in vascular and
neurodegenerative dementias may reﬂect the
involvement of speciﬁc brain regions. For example,
data collected using voxel-based morphometry
showed that in neurodegenerative dementias, the
presence of apathy was independently associated
with tissue loss in the right ventromedial superior
frontal gyrus, disinhibition with tissue loss in the
right ventromedial prefrontal cortex, while aber-
rant motor behaviour with tissue loss in the right
anterior cingulate cortex and left premotor cortex
(45). Furthermore, well-formed visual hallucina-
tions in subjects with DLB have been related
to density of Lewy bodies in the amygdala and
parahippocampus (46). In patients with AD
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agitation and aberrant motor behaviour were
associated with a greater neuroﬁbrillary tangle
burden in the orbital–frontal cortex and apathy in
the anterior cingulate area (47).
On the basis of previous (41) and our results, it
could be suggested that NPS in VaD probably
reﬂect the variability of the location and the
extension of ischaemic damage (cortical vs. sub-
cortical VaD). On the contrary, these and previous
data (41) propose that NPS severity in neurode-
generative dementias, particularly AD, parallel the
progressive atrophy of fronto-temporo-parietal
association cortices (48).
Strengths of this study include its large sample
size, the use of a standardized diagnostic procedure
and adjustment for multiple potential confounders.
However, some methodological issues deserve
mentioning. Caution is needed in extending these
ﬁndings to the general population because the
study sample was recruited in a specialized clinical
setting, which might have introduced a selection
bias. For example, we can hypothesize that sub-
jects with VaD are less represented in our sample
compared with some epidemiological studies
because these patients have often a severe motor
impairment and, consequently, major diﬃculties of
being observed in an outpatient setting. Further-
more, due to the fact that NPI is a caregiver-based
interview, reporter bias cannot be excluded.
Dementia was diagnosed according to clinical
criteria, with inevitably some uncertainty about
the rate of misclassiﬁcation. Without post-mortem
conﬁrmation, a standardized diagnostic procedure
was used with a good between observer agreement,
and clinical diagnoses were supported by brain
imaging assessments. However, it must be
acknowledged that current criteria for DLB have
low sensitivity when Lewy bodies coexist with the
pathological abnormalities of Alzheimer disease
(49). Although analyses were adjusted for major
potential confounders, residual confounding (med-
ical comorbidity, use of psychotropic drugs and
apolipoprotein E4 genotype) (50–53) cannot be
excluded. Concerning the use of psychotropic drug,
however, all patients included in the study were at
their ﬁrst assessment and the majority of cases were
untreated. Finally, the cross-sectional design of the
study may not be optimal since behavioural
disturbances can ﬂuctuate and may not be present
at every examination (54). Moreover, due to the
cross-sectional study design, a relationship between
the type and severity of dementia and NPS
expression can only be hypothesized.
In conclusion, the results of this study suggest
that diﬀerent types of dementias show characteris-
tic behavioural proﬁles. In particular, NPS appear
to be more frequent and severe in degenerative than
in vascular dementia. The frequency of potentially
treatable NPS increases with disease severity in
degenerative dementias, particularly in AD.
Longitudinal data on large samples of subjects are
needed to evaluate the prognostic role of NPS in
diﬀerent types of dementia.
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